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Summary
We examined the effect of the humanT lymphotropic virus type 1 (HTLVI) Tax gene product
on thehuman transforming growth factor 01(TGF-01) promoter . Transfection ofdeleted constructs
ofthe TGF-fl1 promoter revealed regions homologous with AP-1 binding sites that were required
for Tax-induced transactivation of the TGF-(31 promoter. In addition, we examined the expression
and secretion ofTGF-,3 in fresh leukemic cells isolated from patients with adult T cell leukemia
(ATL) and in HTLV1-infectedT cell lines . We report that fresh leukemic cells from ATL patients
constitutively produce high levels ofTGF-01 mRNA and secreteTGF-a1 but not TGF-/32 into
the culturemedium. In addition, long-term ATL cell lines expressed significant amounts of TGF-/31
mRNA as well as detectable levels ofTGF-01 protein . These results suggest a role for Tax in
the upregulation of TGF-a1 in HTLVI-infected cells.
A
dult T cell leukemia (ATL)' is an aggressive, usually
fatal T cell malignancy. Human T lymphotropic virus
type I (HTLVI) has been identified as the responsible infec-
tious agent (1, 2) . Clinical features include skin infiltration
by the leukemic cells, hypercalcemia, and immunosuppres-
sion manifested by a high incidence of opportunistic infec-
tions (1, 3-9) . Some of the clinical features ofATL have been
ascribed to the overproduction of certain cytokknns, such as
TNF-q IDI, or lymphotoxin, by the tumor cells (10-13) .
Recently, excessive amounts ofanother cytokine, transforming
growth factor# (1GF-j3), have alsobeen reported to be secreted
by freshly isolated ATL cells (14-16) .
The overproduction ofTGF-O by these cells is intriguing
since TGF-fl has been shown to have potent immunosup-
pressive properties and to affect calcium metabolism in vitro
(17-25) . In vitro, TGF-S has been shown to depress the
proliferative responses of thymocytes to 1171, T cells to 11,2,
and B cells to B cell growth factors . TGF-0 also suppresses
the generation oflymphokine-activated killer cells and cyto-
'Abbreviations used in this paper. ATL, adult T cell leukemia; CAT,
chloramphenicol acetyltransferase; HTLV 1, human T lymphotropic
virus type 1 ; LTR, long terminal repeat; SELISA, sandwich ELISA ;
TGF, transforming growth factor; TPA, 12-O-tetradeconoyl-phorbil-
13-acetate; TRE, TPA-responsive element .
toxicT cells (19-25) . There is evidence that TGF-a may be
immunosuppressive in vivo as well. patients with glioblastomas
often have impaired cell-mediated immune responses, and their
serum can inhibit mitogen- and antigen-induced prolifera-
tion of normal T cells (26) ; surgical removal of the tumor
reversed the immunosuppression . Purification of the immune-
suppressive factor from a ghoblastoma cell line revealed it to
be TGF-S2, a protein closely related to TGF-,81, with nearly
identical biological properties. It has been postulated that TGFLO
may also be involved in bone resorption sinceTGF-a activity
is increased in cultures of fetal rat calvarial cells incubated
with agents known to stimulate bone resorption, such as
parathyroid hormone, vitamin D3, and ID1 (17) .
In this study, we have confirmed the overproduction of
TGF-O by freshly isolated ATL cells (14) and have demon-
strated that the TGF-# isoform secreted by these cells is ex-
clusively TGF-#1 . Moreover, since the TGF-01 promoter was
found to be transactivated by the HTLVI p40x (Tax) pro-
tein (27-29), we suggest that this may be a potential mecha-
nism by which TGF-a production is increased in ATL cells.
The specific sequence in the 5' regulatory region of theTGF-
0 promoter responsive to Tax was delineated by the use of
deletion mutants and matched a consensus binding site for
the transcriptional factor AP-1 .
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Cells.
￿
Venous bloodanticoagulated with either EGTA, heparin,
or citrate was diluted 1:1 with PBS and then underlayered with
lymphocyte separation medium (Organon Technika, Durham, NC).
Tubes were spun at 600g for30 min at room temperature. Inter-
face cells were washed three timesin serum-free RPMI 1640 and
suspended in one of twoserum-free mediapreparations.Theprepa-
rations used were AIMV (Gibco Laboratories, GrandIsland, NY)
andNutridoma-HU-supplemented (1:100) RPMI 1640. Cultures
were done in T-25 tissue culture flasks prepared in the following
manner: 10 ml ofPBS/25% FCSwasaddedto each flask, and flasks
were allowedto lieflat for 30 min at room temperature. This solu-
tion was removedfrom the flask andthey were then washed thor-
oughly with PBS. ATL PBMC were then introduced into theflask
at cell densities of 1.8-6 x 106/ml and cultured for 48-96 h at
37°C, 95% air/5% CO,. Contents of the flask were removed and
thecells were pelleted.Thesupernatants were spun againat 10,000 g
for 15 minto remove residual cellular debris. With oneof theATL
patients (ATL8), thePBMC were furtherpurified to obtain ahighly
enriched leukemic population. Afterisolation, PBMC were depleted
of monocytes by plastic adherence for 1 h at 37°C. The nonad-
herent lymphocytes were harvested and layered on 46.5% Percoll
(Pharmacia Fine Chemicals, Piscataway, NJ) and spun for 20 min
at 600g. The densecellswere harvested andwashed. These dense
cells were then rosetted with 2-aminoethylisothiouronium bromide
(Sigma Chemical Co., St.Louis, MO)-treated SRBC at afinalcon-
centration of 1% for20 minat 37°C. This suspension was under-
layered with LSM and spun for 20 min at 600g. The redcells in
thepellet were lysedandthelymphocytes were collected. This lym-
phocyte population was suspended in a small volume, to which
theantibodies OKTS (anti-CD8) and3AI (anti-CD7) were added
at 5ttg/ml in RPMI 1640/10% FCS. The suspension wasincubated
for30 min at 4°C. Then, baby rabbit complement (Pel-Freez Bio-
logicals, Rogers, AR) was added at 1:3 (vol/vol), and the suspen-
sion was incubated for 90 min at 37°C. The cell suspension was
then underlayered with lymphocyte separation medium and spun
at 800g for 12 min. The interface cells were collected and put in
culture with RPMI 1640/Nutridoma, as described above. An ali-
quot of these cellswasanalyzed by FRCS and found to be >98.5%
CD2', CD4', CD5', with <1% contamination with cellsbearing
the followingmarkers: CD7, CD8, CD19, CD14, andCD16. In ad-
dition, therewas strong uniform expression of CD25 (Tac) on >88%
of thesecells. Thepresence of alargepredominance ofCD2, CD4',
CD25' cells with near absence of CD7' or CD8' cells indicates
that there were few residual nonmalignant T cells in this popula-
tion. Established HTLVI-infected T cell lines MT-1, MT-2, and
MT-4; T cell lines established from the peripheral blood of ATL
patients, HUT-102; andHTLVI-uninfected lines, Jurkat (Tcell line)
and K-562 (human erythroleukemia), were cultured in RPMI 1640
medium with 10% (vol/vol) FCS. Human lung adenocarcinoma
(A-549) cells were grownin DMEwith high glucosesupplemented
with 5% FCS.
Patient Population.
￿
Eight patients with a histologically confirmed
diagnosis ofATL were studied. Each patient'sdiagnosis wasestab-
lished by the followingcriteria: (a) presence of a circulating pool
of neoplastic mature T cells with indented nuclei; (b) expression
of the tx chain of the IL2-R on >20% of thecirculating lympho-
cytes; (c)demonstrationof aclonal integration oftheHTLVIgenome
in the circulating lymphocytes, as well as a clonal rearrangement of
theTCR ,B gene;and (d)presence ofHTLV-1 antibodies in theserum.
Analysis of TGF01 mRNA and 7r-F-01-CAT mRNA Expression.
PBMC from ATL patients were separated from heparinized venous
bloodby centrifugation over Ficoll-Hypaque. Cells were washed twice
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in RPMI 1640 and then lysed in a guanidinium thiocyanate solution.
Total cellular RNA was isolated by the method of Chirgwin et al.
(30). TotalRNAs from restingTcells, PHA-activated Tcells, purified
normal PBMC, normal B cells, and Staphylococcus aureus Cowan-acti-
vatedBcellswere also isolated as describedabove. Thelevels of specific
transcripts were analyzed by Northern blot analyses. Equal amounts
of RNA (10 Ag), as confirmedby ethidium staining, were subjected
to electrophoresis on 1% agarose gels containing 0.66 M formalde-
hyde, and were transferred to nitrocellulose membranes. Blots were
hybridized using 32P-labeled probes according to the method of
Church and Gilbert (31). Labeling of the 218-bp single-stranded
TGF-/91 probe, complementary to the mature coding region of
human TGF-/31 mRNA, has been described (32).
For the detection of chloramphenicol acetyltransferase (CAT)
mRNA directed by TGF-01 promoters, thelevels ofspecific tran-
scripts were analyzed by the RNase protection technique. RNA
probes were synthesized according to the instructions of the
manufacturer (Promega Biotec, Madison, WI). The EcoRl frag-
ment from thephTG7 (33) wasremovedandreligated. This plasmid
contains a256-bp CATfragment. This plasmid was linearized by
HindIII digestion, andthe linear plasmidwastranscribed with SP6
polymerase.DNase I was addedto digest theDNA template. The
456-nucleotide RNA probe contained 256 by of CAT coding se-
quence.TotalRNA washarvestedaftertransfection of TGF-01 pro-
moterCATconstructs, together with a second plasmidexpressing
the HTLVI p40x protein (34), and analyzed by RNase protection
as describedby Ondeket al. (35) usinggel-purified probes specific
for the CAT mRNA.
P1asmids, Transfections, and CAT Assays.
￿
TGF-01-CAT con-
structs, phTG5, phTG H/B, phTG16, phTG17, phTG19, phTG22,
phTG26, and phTG28 (33, 36, 37), and HTLVI LTR-CAT and
pHTLVpXconstructs (34) have been describedin detail elsewhere.
Transfections were performed by the C2P04 precipitation method
(38) for A-549 cells and by the DEAE-dextran procedure, as de-
scribed by Cross et al. (39), forJurkat and K-562 cells. Approxi-
mately 107 cells of each type were transfected with 10 ug of
plasmid DNA, together with 3 lAg of the pHTLVI-Tax plasmid.
After40 h, cells were harvestedandextracts were assayed forCAT
activity according to the method of Gorman et al. (40). In some
experiments, transfected frequencies were monitored by cotrans-
fectionwith 1 lrgofpSVGH, agrowth hormoneexpression vector.
Quantitation ofthe TGF,81 and TGR,82 Secreted by Cells in Cul-
ture. TGF-O secreted from the cells wasquantitated by the sand-
wich ELISAs (SELISAs) for TGF-01 andTGF-{32 usingboth turkey
andrabbit neutralizing polyclonal antibodies against native TGF-
/3s (41).
Results
Effect ofTaxon TCF,81 Promoter Constructs andIderitification
ofTGF,81 Promoter RegionsRequiredforTax Transactivation. To
understand theeffect of the HTLV-1 provirus on theTGF-a1
gene,we cotransfected plasmids containing sequenceslocated
5' to theupstream transcriptional start site (the firstpromoter,
phTG5), andlocated between the two major transcriptional
initiation sites of the TGF-01 gene (the second promoter)
linked to thebacterial CAT gene (40) (Fig. 1 and seebelow)
into A-549 cells, Jurkat cells, and K-562 cells, together with
a HTLV-1 Taxexpression vector. As shownin Fig. 1, the first
promoter CAT (phTG5) and the second promoter CAT
(phTG16), as well as that of HTLVI LTR CAT (34), were
transactivated by Tax protein in all cells tested; expressionK-562
￿
Jurkat
phTG5 phTG16pU3RCAT
￿
phTG5 phTG16pU3RCAT
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of phTG5 and pHTG16 is induced 7-19-fold in response to
transactivation by Tax protein . These results suggest that
common promoter elements required for Tax transactivation
are present in the first and second promoters of the TGF-f1
gene . RNase protection analysis with an SP6 complemen-
taryRNA probe showed that the TGF-#1 CAT gene exhibited
an increased level ofRNA in cotransfection assays with the
HTLUI Tax expression vector, but not with pGEM4 (Fig .
2) . It thus appears that transactivation of the TGF-R1 pro-
moter by the Tax protein is at the transcriptional level .
To identify the specific sequences required for Tax transac-
tivation, we used a series of 5' deletion mutants of the TGF-
#1 promoters linked to the CAT gene . As shown in Fig. 3,
the first promoter sequences of the TGF-01 gene positioned
between nucleotides -453 and -323 were required for op-
timal CAT induction by Tax protein . The second promoter
of the TGF-,Q1 gene was also transactivated by Tax protein .
The expression of plasmids phTG16, phTG17, phTG19, and
phTG26 was increased by the Tax protein, whereas the Tax
stimulation dropped almost to the basal levelwhen sequences
between +150 and +173 were deleted (phTG22) . Tax stimu-
lation again dropped substantially upon deletion of sequences
between +247 and +267 . These data suggest that the majority
ofactivation by Tax protein is mediated by promoter sequences
between positions -453 and -323 of the first promoter and
between positions +150 and +173 and +247 and +267 in
the second promoter of theTGF-#1 gene. These critical pro-
moter sequences required for the Tax induction in TGF-01
promoters contain sequence elements (TGTCTCA, -371 to
-365 ; TGAGACGA, +160 to +167 ; and TGAGACT, +256
to +262) with a high degree of similarity to the AP-1 com-
plex binding sites found in the collagenase (42) and metal-
lothionein promoters (43) . These TGF-01 promoter elements
play an important role in transcriptional activation of the
TGF-01 gene mediated by various inducers, including TGF-
01 (36, 37, 44) and 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) (36, 45) .
Expression ofTGRti1 mRNA inATL Patients and HTLV-I-
infected Cell Lines. To determine the levels ofTGF-01 gene
expression in fresh leukemic cells isolated from patients with
ATL and in HTLV-I-infected T cell lines, Northern blot anal-
yses were performed with total RNA isolated from these leu-
kemic cells . The 2.4-kbTGF-01 mRNA was readily detected
in six of six primary leukemic cells from patients with ATL
A-549
phTG5 phTG16 pU3RCAT
Figure 1 .
￿
Activation of the plasmids
phTG5, phTG16, and pHTLVLTR-CAT
(pU3RCAT) by Tax protein. Each of the
plasmids was transfected into Jurkat cells, K-
562 cells, and A-549 cells either with or
without 3 jig of a p40X-producing plasmid .
40 h later, the cells were harvested and CAT
enzyme activity was determined. pHTLV
LTR-CAT (pU3RCAT) was used as a control
for the Tax transactivation .
Figure 2 .
￿
RNase protection analysis of TGF-S1-CAT gene expres-
sion . 10 Fig of TGF-#l-CAT constructs, together with 3 ug of a p40'-producing
plasmid or 3 14g of the pGEM4 vector used as a con-
trol was transfected into A-549 cells . 40 h later, the total RNA was
extracted and RNA was analyzed for the level of correctly initiated
CAT transcript by RNase protection (35) . The size of the CAT ribo-
probe is 480 nucleotides, whereas the size of the fragment protected
from RNase digestion is 256 nucleotides.Figure 3 .
￿
Tax stimulation of 5'
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ity, expressed as the percentage of chloramphenicol transacetylation, was measured after 40 h, for a representative experiment using A549 cells,
as described (40) . Transfection frequencies were monitored by cotransfection with 1 ug of pSVGH, a growth hormone expression vector.
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(Fig. 4, A and B), and in four of four HTLVI-infected cell
lines (Fig. 4 C) . TGF-(31 mRNA was detected in thePHA/
PMAinducedJurkat RNA (positive control), whereas unin-
ducedJurkat cells, control restingT cells, and controlPBMC
had low levels of TGF-/31 mRNA (Fig. 4, A and C) . Sig-
nificantly higher TGF-/31 mRNA levels were observed in
freshly isolated ATL PBMC in comparison with control
PBMC or control resting T cells (Fig . 4A) . InRNA from
five of six of theATL cases, TGF-a1 mRNA levels were equal
to or greater than the levels seen in ATIrderived cell lines
or induced Jurkat cells (Fig. 4, B and C) .
TCF-,B Secretion by HTLVI-infectedT CellLines and Freshly
IsolatedATL Cells.
￿
Hut-102,MT1,MT2, Jurkat, and normal
Figure 4.
￿
Detection of TGF-131 mRNA in HM-1-infected cell lines and primary leukemic T cells. 10 1Ag RNA from control resting T cells
(A) ; control PBMC (A) ; primary leukemic cells (ATL 2-7) (A and B) ; HTLV-1-infected T cell lines (MT1, MT2, MT4, andHUT102) (C) ; and
noninfected T cell line Gurkat) (C) were hybridized to a radiolabeled TGF-01 probe.
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T and B cells were cultured at 37°C for 48 h in serum-free
medium . The culture supernatant was harvested by centrifu-
gation, and the amounts of ME-01 and TGF-02 secreted
from the cells were measured by SELISA . Supernatants con-
ditioned by unactivated T cells or B cells contain low levels
ofTGF-0 biological activity (<0.5 pM), while supernatants
from PHAactivated T cells and SAC-activated B cells had
levels 10-50-fold higher (Table 1) (20) . However, as shown
in Table 1, supernatants from the unstimulated PBMC de-
rived from the ATL patients secreted levels of TGF-0 equal
to or substantially greater than those of the activated T and
B cells . Since the increased TGF-0 secretion from the ATIT
derived PBMC could possibly result from the induction ofCells were plated at 106/ml and cultured for 48 h in serum-free me-
dia as described in Materials and Methods. Levels of TGF-01 and 02
peptides were measured by specific and sensitive SELISAs. Condi-
tioned media TGF-01 and TGF-/32 measured by the SELISAs were
calculated using cubic and quadratic regression equations with Dy-
natech's immunosoft program. All values shown represent the aver-
age of the three determinations ± 1 SD from the mean.
TGF-0 productionin another cell type present in the PBMC
preparation, we generated a highly purified population of
malignant ATL cells and examined the levelof TGF-01 secreted
(ATL8). The level of TGF-/31 secreted from the purified leu-
kemic cells was much higher than that of unactivated T cells.
The type of TGF-0 secreted by HTLVI-infected cells was
determinedby a SELISA using antisera specific for either TGF-
01 or TGF-02 (41). TGF-0 secreted from all of the tested
cells was predominantly TGF-S1; levels ofTGF-(32 were low
to undetectable (Table 1). These results demonstrate that
HTLVI-infected cells secrete relatively large amounts ofTGF-
01 protein.
Discussion
The present studies strongly suggest that Tax protein acti-
vates the gene for TGF-S1 through a distinct DNA element,
the TPA-responsive element (TRE), which is also required
for activation by TPA or TGF-01. THE motifs have been
shown to bind the AP-1 complex consisting of the Jun/Fos
dimer. In both the first and second promoters of the TGF-01
gene, the DNA motifs that mediate the responses to Tax pro-
tein and to TGF-01 autoinduction are identical.
The HTLVI Tax protein (27-29) is a potent transcriptional
activator of its own long terminal repeat (LTR) promoter
and a number of cellular genes. It is known that the transac-
tivation function of Tax is highly pleiotropic since Tax-
responsive genes (e.g., IL2-Roi [39, 46], 11,2 [46-48], GM-
CSF [49], and IIr3 [50]) share little sequence homology in
their regulatory sequences. We have documentedthat the es-
sential Tax-responsive element within the HTLVI LTR con-
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sists of a triply reiterated TGACGTCT motif (51, 52). In
fact, it has been experimentally demonstrated that the HTLVI
LTR is both a CAMP and a phorbol ester responsive element.
Recently, we have found that the TGACGTCT element for
the HTLVI LTR is a bona fide binding site for AP-1 and
functionally responds to activationby v~un aeang et al., manu-
script in preparation). Our present observation that Tax also
activates the TGF-01 promoter through the AP-1/Jun motifs
suggests that this described transactivation phenomenon may
be physiologically relevant and may functionally occur through
the signal transduction pathway that is postulated in Tax ac-
tivation of the HTLVI LTR (51, 52). Our results are also
strengthened by the observation that expression ofc-fos, which
is one of the components of the AP-1 complex that binds
to the TRE, is also transactivated by the Tax protein (53).
The mechanism for interaction of Tax protein with the
AP-1 complex remains to be clarified. It is unlikely that Tax
binds to DNA directly or leads to de novo synthesis of cel-
lular factors that confer activation. One possible hypothesis
might be that Tax expression results in the post-translational
modification of a constitutively expressed transcription factor
from an inactive to an active form, or that Tax participates
directly in the formation of an active transcription complex.
Thus, transactivation of TGF-ail gene expression by Tax could
proceed via an indirect, rather than direct, mechanism.
We also demonstrated high levels of constitutive expres-
sion ofthe TGF-(31 gene in leukemic cells from ATL patients,
as well as in HTLVI-infected T cell lines, confirmingprevious
results (14). Since TGF-0 mRNA levels from other leukemic
cells, such as acute myelogeneous leukemia, acute lymphatic
leukemia, and chronic myelogeneous leukemia, were low to
undetectable (14), the fact that ATL cells produced high levels
of TGF-(31 mRNA suggests that this event is directly in-
duced by HTLVI. In contrast to primary tumor cells, long-
term ATL cell lines produced variable amounts of TGF-01
mRNA.
The altered regulation by Tax of a variety of host genes,
including those associated with T cell activation and prolifer-
ation, has led to speculation that Tax expression plays an es
sential role in the pathogenesis of HTLVI-associated diseases.
The high level of TGF-/31 gene expression associated with
ATL cells suggests that this mediator may also play an im-
portant role in the pathological changes associated with this
leukemia. However, efforts to date have failed to demonstrate
Tax mRNA in fresh leukemic cells (54). Thus, expression
of TGF-(31 in the circulating cells of ATL patients is similar
to the IIT2-Rot (Tac), in that high levels of constitutive ex-
pression ofboth genes are easily demonstrated from fresh leu-
kemic cells in the absence of Tax. Theoretically, transactiva-
tion of TGF-/31 and IIr2-Ra (Tac) could occur early in the
course of HTLVI infection, priming the T cells for a second
"hit", resulting in leukemogenesis. Thus, the circulating ATL
cells would be in a terminally differentiated, autonomous state
and may no longer require Tax expression for proliferation.
Alternatively, Tax expression maybe limited to microenviron-
ments inwhich cells are rapidly dividing, i.e., malignant lymph
nodes. Finally, as a regulatory message, Tax mRNA may be
present in minute quantities and may have a very short half-
Table 1. TGF,B Levels
Cells
Assayed by SELISAs
TGF-(31 TGF-(32
PM PM
Normal T cell <0.50 <0.50
PHA-activated T cell 24.40 ± 0.4 <0.05
Normal B cell <0.50 <0.05
SAC-activated B cell 7.92 ± 0.2 <0.50
Jurkat <0.50 <0.50
MT1 4.43 ± 0.5 <0.50
MT2 6.92±0.5 0.64±0.1
HUT102 7.10 ± 0.4 <0.50
ATLI 80.40 f 3.7 <0.50
ATL2 39.12 ± 2.3 1.09 ± 0.1
ATL3 8.91 t 0.7 <0.50
ATL8 10.70 t 0.2 <0.50life, rendering its detection extremely difficult. Using a sen-
sitive PCR technique, we have occasionally detected Tax
mRNA from ATL PBMC (unpublished observations, C.L.
Tendler) . Interestingly, Maeda et al. (55) have shown that
many long-term cultured ATL cell lines no longer correspond
to the original primary tumor cells based on the clonal pat-
tern of rearrangement within the TCR a chain gene locus
or in the integration site of the HTLV1 provirus. Thus, it
is clear that these two HTLVI-infected T cell populations
exhibit potentially important genetic and functional differ-
ences.
TGF-0 is produced by mitogen-activated T and B cells,
while nonactivated cells produce very low levels of TGF-(3.
In contrast, nonmitogen-activated HTLVI-infected cell lines
and freshly isolated leukemic cells from patients with ATL
secreted levels of TGF-(3 equivalent to and/or in excess of
mitogen-activated lymphocytes. Both normal lymphocytes
and the HTLVI-infected cells produced exclusively TGF-0l,
with the exception of small amounts of TGF-02 produced
by MT2 cells and one of the patient's cells.
The TGF-0 produced by normal lymphocytes is predomi-
nantly in a latent form that is unable to bind to the TGF-/3
receptor. This latent form is a complex between the remainder
of the TGF-0 precursor, mature TGF-a, and a third TGF-a
binding protein (56, 57). In vitro, exposure to low pH or
heat results in dissociation of the complex and the release
of active TGF-IQ (56) . The mechanism by which TGF-0 is
activated in vivo is poorly understood, but it may involve
proteolytic enzymes or exposure to the appropriate microen-
vironment. Similar to normal lymphocytes, the TGF-0 pro-
duced by the ATL cell lines appears to be predominantly la-
tent. All the supernatants used in the SELISA were acid or
heat inactivated before testing, which would activate any la-
tent TGFLS present. However, the supernatants were also tested
using a CCD64 assay (58), a biologic assay that measures
active TGF-0. Active TGF-a was detected in the superna-
tants conditioned by the ATL cells only after heat activation
(A. B. Roberts, unpublished observation). This is in con-
trast to the findings of Niitsu et al. (14), who reported that
much of the TGF-a produced by ATL cells was active. The
distinction between the production of predominantly latent
vs. active TGF-a is important. The half-life of active TGF-(3
in the circulation is exceedingly short (N3 min) (59), while
the half-life of latent TGF-/3 is nearly 2 h (L. Wakefield, per-
sonal communication). Thus, the production of active TGF-
0 by a cell is likely to have an effect only in the immediate
environment of the secreting cells, while the production of
latent TGF-a by a cell may result in a more long-rangeeffect.
Cellular and humoral immune responses are markedly im-
paired in patients with ATL. Abnormalities include disor-
dered helper and suppressor T cell function, impaired mitogen
responsiveness, decreased killer cell induction, and depressed
B cell Ig synthesis (60-62). Additionally, immunosuppres-
sive factors have been detected in HTLVI-infected ATL sera
and ATL culture supernatants (63, 64). X-irradiated leukemic
cells from ATL patients suppress the PWM-induced Ig syn-
thesis by control PBMC (65). The excessive production of
TGF-(3 by ATL cells in vivo could account for many of these
immunological abnormalities. TGF-(3 has been shown in vitro
to impair both T and B cell proliferation, to inhibit NK cell
induction and cytotoxic T cell induction, and to depress B
cell Ig secretion (19-25). The in vitro effects of TGF-/3 and
the observed immunosuppression in ATL patients are strik-
ingly similar. Additionally, the excessive production ofTGF-(3
by ATL cells may offer a selective advantage. Increased levels
of TGF-a may suppress the very immune cells responsible
for the elimination of the tumor cells.
TGF-0s are important in the regulation of many other cell
types as well. Of interest to this study, they have been found
to be important in the processes ofbone resorption and new
bone formation (17, 18). One of the important clinical fea-
tures of ATL patients is the frequent hypercalcemia (1, 3-9).
The findings that bone resorbing factors are present in the
in vitro culture supernatants of ATL cells has suggested that
osteoclast-activating factors are produced by the ATL cells
themselves. Several factors, including 1140 and TNF-(3, have
been detected in these supernatants and have been suggested
to be involved in the pathogenesis of the hypercalcemia (12,
13). It is likely that TGF-(3 is involved as well, either by itself
or in combination with these other cytokines. To establish
firmly a relationship between TGF-IQ production and ATL
associated changes in calcium metabolism and immune com-
petence, prospective studies correlating TGF-(3 production
with changes in bone turnover, osteoclast activation, and im-
mune function are needed.
In conclusion, we have shown that the increased produc-
tion of TGF-0 by ATL cells and some HTLVI-infected cell
linesmay be related to the transactivation ofthe TGF-0 pro-
moter by the HTLVI-derived protein, Tax. Using deletion
mutants of the TGF-0 promoter, we have mapped the Tax-
responsive element to the AP-1-binding sites in the TGF-(3
promoter. The excessive production of TGF-ail may be im-
portant in the pathogenesis of the immunosuppression and
hypercalcemia associated with ATL.
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